Acticor Biotech Fab Fragment Development & Manufacturing

Founded in 2013 as a spin-off of Inserm, the French National Institute of Health and Medical Research, Acticor Biotech is developing an innovative drug for treating the acute phase of ischemic stroke. Glenzocimab (ACT017) is a humanized Fab fragment of a monoclonal antibody, targeting platelet glycoprotein VI (GPVI) to inhibit its action. This target is involved in thrombus growth but not in physiological hemostasis, which reduces the bleeding risk associated with its inhibition.

Starting with a set of CHO-S cell lines and a timeline of 18 months, Acticor Biotech sought a partner that could conduct clone selection, establish the master cell bank, develop an optimized process for producing the Fab fragment, and manufacture GMP batches to initiate a clinical trial. The success of this project was crucial for the future of the company and its therapeutic candidate.

Explore the outcomes of implementing an accelerated approach to process development and manufacturing that did not expose Acticor Biotech to any additional risk.